Products
Products
Explore our advanced sequencing products for turning complex molecular signals into high-confidence readouts across clinical testing, RNA quality control, and translational methylation programs.
NeuroLens®
Neuron Cell-Death Test
RNA Clarity™
RNA Vaccine QC
MethylMap™
Native-Read Methylation Sequencing
Older woman discussing a clinical diagnosis with a female doctor who is reviewing a tablet in a medical office.
Services
Services
End-to-end sequencing services supporting genomic, epigenomic, and transcriptomic analysis, from experimental design and assay development to bioinformatics, interpretation, and data delivery.
Applications
Applications
Explore how our products and services help solve difficult biological and genomic problems, from liquid biopsy signals to complex regions and emerging biomarker development.
Hard-to-Sequence Genes & Complex Regions
Liquid Biopsy cfDNA Analysis
Targeted Panel Development
Close-up of overlapping teal and green curved panels with light reflections and a smooth gradient.
Company
Company
Building the future of precision diagnostics through sequencing innovation, scientific rigor, and collaborative partnerships.
About Us
Partnerships
Team
Careers
Building with a black facade featuring white 3D letters spelling 'RENEW' and a geometric logo.
Resources
Contact
  • Company
  • Company
    Building the future of precision diagnostics through sequencing innovation, scientific rigor, and collaborative partnerships.
    About Us
    Partnerships
    Team
    Careers
    Building with a black facade featuring white 3D letters spelling 'RENEW' and a geometric logo.

Complex Biology. Clearer Answers.

Clinical diagnostics and research servicesspanning methylation, RNA, long-read genomics,bioinformatics, and assay development.

Start A Project

An Integrated Model for Impact

Renew builds platforms with a single goal: Improve patient care. With proprietary sequencing technologies and specialized analytical workflows, we uncover biological signals that conventional approaches often miss.

Our integrated technology model, which combines these workflows with CAP/CLIA laboratory infrastructure, transforms these molecular insights into real-world healthcare impact.

Contact
Scientist in a laboratory using precision equipment to prepare a biological sample.

Clinical Products and Solutions

Renew translates advanced molecular technologies into clinical diagnostics, research tools, and operational workflows.

  • Clinical ProductNeuroLens®

    Blood-based liquid biopsy for detecting neuron- and glia-associated cfDNA signals linked to active neurodegeneration.

    More about NeuroLens®

  • QC ProductRNA Clarity™

    Native RNA sequencing workflow for multi-attribute RNA therapeutic characterization, QC, and lot release testing.

    More about RNA Clarity™

  • SolutionMethylation Solutions

    Native DNA methylation workflows enabling broader epigenetic coverage and higher-fidelity methylation profiling.

    More about Methylation Solutions

  • SolutionHard-to-Sequence Genes

    Long-read DNA sequencing workflows for resolving complex variants, repeats, haplotypes, and structural variation.

    More about Hard-to-Sequence Genes

Built. Measured. Applied.

Green metallic 3D text showing the percentage 97.6%.
AUC - Alzheimer's disease discrimination in multi-disease cohorts
Green metallic text displaying the number and letter '30x'.
Increased CpG coverage compared to the Illumina Array
Shiny teal 3D style number 90 percent on black background.
Accuracy of long-read PGx panel for CYP2D6 of GIAB
Shiny teal 3D text displaying the number 99.1%.
Analytical Accuracy of cell classification for cfDNA diagnostic use cases
Glossy teal 97 percent symbol on a transparent background.
Regional methylation accuracy with targeted gDNA native-read sequencing
Turquoise 3D text showing greater than 90 percent symbol on black background.
Chromosome arms covered for reliable arm-level telomere length estimates
Scientist with a mask checking fluids in a lab
June 18, 2026
Renew Advances Epigenetic Diagnostics Through Path Fertility’s NOA Guide
Path Fertility’s NOA Guide uses epigenetic diagnostics to support surgical decision-making for non-obstructive azoospermia, with Renew as the clinical testing provider.
Text Link
Scientist with a mask checking fluids in a lab
June 18, 2026
Renew Expands Targeted Multiomic Sequencing Through Agilent Collaboration
Direct Targeted Methylation Sequencing combines Agilent enrichment with Renew’s native-read workflow to analyze genetic and epigenetic variation in targeted regions.
Text Link
Scientist with a mask checking fluids in a lab
June 18, 2026
Renew and Oxford Nanopore Accelerate Methylation Sequencing Toward Clinical Use
Renew and Oxford Nanopore are advancing Direct Whole Methylome Sequencing to capture genome-wide methylation, sequence, and hydroxymethylation signals.
Text Link

In The Press

Heading

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse varius enim in eros elementum tristique. Duis cursus, mi quis viverra ornare, eros dolor interdum nulla, ut commodo diam libero vitae erat. Aenean faucibus nibh et justo cursus id rutrum lorem imperdiet. Nunc ut sem vitae risus tristique posuere.

Working With The Best

Oxford Nanopore Technologies Logo
Oxford Nanopore Technologies
Advancing Direct Whole Methylome Sequencing with Oxford Nanopore, a native-read approach designed to move methylation analysis beyond bisulfite sequencing and arrays.
boston heart logo
Boston Heart Diagnostics Partnership
A strategic distribution relationship with Boston Heart Diagnostics supports NeuroLens products and direct methylation sequencing services for blood-based brain cell death testing.
twist logo
Twist Bioscience
Custom hybridization panels developed with Twist support Oxford Nanopore-based long-read targeted sequencing for complex genomic regions and application-specific targets.
Agilent Technologies
Direct Targeted Methylation Sequencing products and services combine Agilent enrichment with Renew’s native-read workflow for targeted genetic and epigenetic analysis.

Questions & Answers

Questions & Answers

How can Renew's sequencing solutions support my research or project?

Renew delivers native-read, long-read sequencing to generate integrated genomic and epigenomic insights in single assays, supporting discovery, biomarker development, and scalable clinical translation.

Are Renew's NGS services suitable for clinical research?

Yes. Renew offers scalable, clinical-ready sequencing workflows designed for translational studies, cohort-scale research, and precision clinical testing, including platforms.

Is Renew’s clinical laboratory CLIA certified?

Yes. Renew is CLIA certified and CLEP- and FDA-ready. Our team supports programs from early discovery through clinical validation and patient testing, with expanding regulatory scope for IVDs, companion diagnostics, and global compliance (e.g., ISO 13485, ISO 15189, IVDR).

What NGS sequencing options are offered at Renew?

Renew offers whole-genome and targeted genomic, epigenomic, and transcriptomic sequencing using Oxford Nanopore technology, including Direct Whole Methylome Sequencing (dWMS), Direct Targeted Methylation Sequencing (dTMS), and standard ONT sequencing services.

How can I get started with Renew?

Explore our service offerings. For tailored research or development support, contact our team to discuss your project goals.

Discover Your Next Breakthrough
Discover More
Join For Updates
Success! Thank you for joining our newsletter.
Oops! Something went wrong while submitting the form.
© 2026 Renew Biotechnologies | All Rights Reserved
CAP 7654476 | CLIA 46D2309073